Article: Tips for successful editing in T cells
Gene editing by CRISPR has led to significant advances in immunotherapy development. CRISPR can be used to rapidly knock out cell surface receptors, thereby limiting concerns of rejection by the immune system if the T cells engineered were not collected from the recipient. CRISPR also offers the ability to knock-in specific sequences into any gene, including chimeric antigen receptors (CARs) which target activated T cells to a specific tumor recognition site.
Related content from this organisation
- Targeting phosphodiesterase 3A: discovery of a promising cancer therapy
- Screening for COVID-19 drugs
- Assessing compound activity to accelerate drug discovery
- Why some screening hits are a PAIN
- Application note: Effectiveness of CRISPR‑Cas9 using pools of synthetic crRNAs in high-content analysis screening experiments